Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04629508
Title To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

myelofibrosis

Therapies

Itacitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.